# Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients

> **NCT05443932** · PHASE4 · UNKNOWN · sponsor: **Medical University of Vienna** · enrollment: 32 (estimated)

## Conditions studied

- Urolithiasis
- Hyperoxaluria

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Hydrochlorothiazide

## Key facts

- **NCT ID:** NCT05443932
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-04
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05443932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05443932, "Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05443932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*